Credit: Shutterstock photoTandem Diabetes Care, Inc.TNDM was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $39.95 -$51.17 in the past one-month time frame, witnessed a sharp increase yesterday.
The move came after the company raised sales guidance for 2018 and provided upbeat views on third-quarter 2018 sales results.
The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Tandem Diabetes Care. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Tandem Diabetes Care currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Tandem Diabetes Care, Inc. Price
Tandem Diabetes Care, Inc. Price | Tandem Diabetes Care, Inc. Quote
Investors interested in the Medical - Instruments industry may consider a better-ranked stock like Penumbra, Inc. PEN , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is TNDM going up? Or down? Predict to see what others think: Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
